Clinical trials: Muscle Invasive Bladder Urothelial Carcinoma
Bladder Cancer
Preoperative MPDL3280A in Transitional Cell Carcinoma of the Bladder
ABACUS is an open-label, international, multi-centre, window of opportunity phase II trial for patients with histologically confirmed (T2-T4a) transitional cell carcinoma of the bladder.
- Trial name
- ABACUS (NCT02662309)
- Testing
- MPDL3280A
- Where
- 20 sites in France, Netherlands and 2 more
- Volunteers
- 96 people
- Sponsor
- Queen Mary University of London
Localized Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8
Home-Based Physical Activity Program With Digital App Versus Health Education Group for Improving Physical Activity Among Patients With Non-muscle Invasive Bladder Cancer, The EMPOWER Trial
This clinical trial compares how well a home-based personalized physical activity program (PAP) that is delivered by a digital application (app) (the ExerciseRx app) works compared to health education in improving physical…
- Conditions
- Localized Non-Muscle Invasive Bladder Urothelial Carcinoma, Stage 0a Bladder Cancer AJCC v8, Stage 0is Bladder Cancer AJCC v8, Stage I Bladder Cancer AJCC v8
- Trial name
- EMPOWER (NCT07302230)
- Testing
- Internet-Based Intervention, Best Practice, Exercise Intervention
- Where
- United States
- Volunteers
- 100 people
- Sponsor
- University of Washington
Bladder Cancer, Bladder Cancer Recurrence
Predictive Value of E-cadherin, β-catenin and SOX4 in Recurrence and/or Progression of Non-muscle Invasive Urinary Bladder Transitional Cell Carcinoma. A Retrospective Study
Bladder cancer is common tumor in which recurrence and/or progression in patients undergoing TUR has been reported to range between 30% and 80% in patients with NMIBC TCC.
- Trial name
- NCT07657299
- Where
- Egypt
- Volunteers
- 30 people
- Sponsor
- Ain Shams University
Non-muscle Invasive Bladder Cancer (NMIBC)
Phase 1/2 Study of ABI-009 in Nonmuscle Invasive Bladder Cancer
Purpose of this study is to determine appropriate dosing of ABI-009 and evaluate the safety and anti-tumor activity of ABI-009 in treatment of non-muscle invasive bladder cancer
- Trial name
- NCT02009332
- Testing
- ABI-009, Gemcitabine
- Where
- 2 sites in United States
- Volunteers
- 21 people
- Sponsor
- Aadi Bioscience, Inc.
Urothelial Carcinoma of the Bladder, Muscle Invasive Bladder Cancer (MIBC)
Perioperative Systemic Therapies in Muscle-Invasive Bladder Cancer (GUARDIANS)
This is a multicenter, non-interventional, prospective and retrospective observational patient registry study of adults with muscle-invasive bladder cancer receiving perioperative systemic therapy as part of routine clinical…
- Trial name
- GUARDIANS (NCT07855926)
- Testing
- Perioperative Systemic Therapy Registry
- Where
- Germany
- Volunteers
- 500 people
- Sponsor
- LMU Klinikum
Urothelial Carcinoma, Non Muscle Invasive Bladder Cancer
Brazilian Reality of Urinary Bladder Cancers - BRA-BLADDER
A national, multicenter, non-randomized, retrospective, observational study (Real-World Evidence-RWE) aimed at analyzing clinical presentation profiles and demographic characteristics of patients with early urothelial bladder…
- Conditions
- Urothelial Carcinoma, Non Muscle Invasive Bladder Cancer, Muscle-invasive Bladder Cancer
- Trial name
- NCT05945108
- Where
- 5 sites in Brazil
- Volunteers
- 400 people
- Sponsor
- AstraZeneca
Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma (UC)
Immune-Stromal Landscape in Muscle-Invasive Bladder Cancer
Bladder cancer is a significant global health issue. When the cancer spreads into the muscle layer of the bladder (muscle-invasive bladder cancer), a common treatment is the surgical removal of the bladder (radical cystectomy).
- Conditions
- Muscle-Invasive Bladder Carcinoma, Urothelial Carcinoma (UC), Bladder Cancer, Muscle-Invasive Urothelial Bladder Carcinoma
- Trial name
- NCT07525349
- Volunteers
- 100 people
- Sponsor
- Assiut University
Muscle Invasive Bladder Cancer, High Risk Urothelial Carcinoma of the Upper Urinary Tracts
Dose Dense MVAC for Muscle Invasive Bladder Cancer
Standard treatment for early stage bladder cancer is chemotherapy with methotrexate (M), vinblastine (V), adriamycin (A), and cisplatin (C) followed by surgical removal of any remaining cancer and the bladder with the intent of…
- Trial name
- NCT01031420
- Testing
- single arm dose dense MVAC
- Where
- 2 sites in United States
- Volunteers
- 54 people
- Sponsor
- Fox Chase Cancer Center
Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma
Vesical Imaging-Reporting and Data System (VI-RADS) Followed by Photodynamic Trans-urethral Resection of Bladder Tumours (PDD-TURBT) to Avoid Secondary Resections (Re-TURBT) in Non-Muscle Invasive Bladder Cancers (NMIBCs)
Background: In European Association of Urology (EAU) Guidelines, the vast majority of non-muscle-invasive bladder cancers (NMIBCs) undergo a primary transurethral resection of the bladder tumor (TURBT) followed by a repeat TURBT…
- Conditions
- Non-muscle-invasive Bladder Cancer, Non-Muscle Invasive Bladder Urothelial Carcinoma, High Risk Non-Muscle Invasive Bladder Urothelial Carcinoma
- Trial name
- CUT-less (NCT05962541)
- Testing
- PDD-TURBT with hexaminolevulinate (Hexvix®), Power Led Saphira (TM)
- Where
- Italy
- Volunteers
- 327 people
- Sponsor
- University of Roma La Sapienza
Upper Tract Urinary Carcinoma, Muscle-invasive Bladder Cancer
Neoadjuvant Treatment of Upper Urinary and Muscular Invasive Bladder Urothelial Carcinoma
Few previous studies focused on the neoadjuvant treatments of upper urinary or bladder cancer, especially chemotherapy combined with immunotherapy, however, available data of retrospective studies showed this neoadjuvant…
- Trial name
- NCT04099589
- Testing
- Toripalimab
- Where
- China
- Volunteers
- 64 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
Urothelial Carcinoma Bladder, PD-1 Inhibitor
Bladder Sparing Treatment of Tislelizumab, Gemcitabine and Cisplatin for Patients With PD-L1 Positive Muscle Invasive Bladder Cancer
This is a phase II open label single-arm prospective study aiming to investigate the efficacy of PD-1 inhibitor Tislelizumab combined with conventional gemcitabine and cisplatin as bladder sparing treatment for patients with…
- Trial name
- NCT05401279
- Testing
- Tislelizumab, Gemcitabine, Cisplatin
- Where
- China
- Volunteers
- 20 people
- Sponsor
- RenJi Hospital
Bladder Cancer
Sunitinib in Treating Patients With Locally Advanced Bladder Cancer
RATIONALE: Sunitinib may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth and by blocking blood flow to the tumor.
- Trial name
- NCT00526656
- Testing
- sunitinib malate
- Where
- United States
- Volunteers
- 9 people
- Sponsor
- Case Comprehensive Cancer Center
Muscle-invasive Transitional Cell Carcinoma of the Bladder
Study of Intratumoral REOLYSIN® in Combination With Gemcitabine and Cisplatin as Neoadjuvant Therapy in Muscle-invasive Transitional Cell Carcinoma of the Bladder
The purpose of this study is to investigate the safety and efficacy of intratumoral REOLYSIN® therapy alone and in combination with standard neoadjuvant gemcitabine and cisplatin in muscle-invasive bladder cancer.
- Trial name
- NCT02723838
- Testing
- REOLYSIN®, Gemcitabine, Cisplatin
- Sponsor
- Oncolytics Biotech
Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8
Sacituzumab Govitecan Before Radical Cystectomy for the Treatment of Non-Urothelial Muscle Invasive Bladder Cancer
This phase II trial tests whether sacituzumab govitecan given before radical cystectomy works in treating patients with non-urothelial bladder cancer.
- Conditions
- Muscle Invasive Bladder Carcinoma, Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
- Trial name
- NCT05581589
- Testing
- Lymphadenectomy, Radical Cystectomy, Sacituzumab Govitecan
- Where
- United States
- Volunteers
- 4 people
- Sponsor
- University of Washington
Lung Cancer (NSCLC)
Snakehead Fish Extract and Curcumin Co-Supplementation in Advanced Lung Cancer on Inflammation, Nutritional Status, and Quality of Life
Background: Patients with advanced lung cancer receiving systemic therapy often experience nutritional decline, systemic inflammation, and impaired quality of life.
- Trial name
- BMI (NCT07906626)
- Testing
- Snakehead Fish Extract and Curcumin
- Where
- Indonesia
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Universitas Sumatera Utara
Bladder Cancer Cell Transitional
Sarcopenia and NMIBC Prognosis Study
The goal of this observational study is to evaluate whether body composition abnormalities (sarcopenia, myosteatosis, and obesity) and nutritional status influence the risk of recurrence and progression in adult patients with…
- Trial name
- SARC-NMIBC (NCT07285408)
- Volunteers
- 150 people
- Sponsor
- General Hospital Sveti Duh
Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8
Pembrolizumab and Combination Chemotherapy Before Surgery for the Treatment of Muscle-Invasive Bladder Cancer
This pilot study is evaluating how well pembrolizumab and combination chemotherapy before surgery work for the treatment of specific types of muscle-invasive bladder cancer that have unusual appearance (variants).
- Conditions
- Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Muscle Invasive Bladder Carcinoma
- Trial name
- NCT04383743
- Testing
- Cisplatin, Doxorubicin, Methotrexate
- Where
- United States
- Volunteers
- 17 people
- Sponsor
- University of Washington
Non-Muscle Invasive Bladder Urothelial Carcinoma
Irinotecan Liposomes Combined with Epirubicin in Recurrent Non-muscle Invasive Bladder Urothelium Carcinoma After Anthracyclines Treatment
The goal of this clinical trial is to learn the dose-limiting toxicity of the new combined treatment with irinotecan liposomes (intravenous injection) and epirubicin (intravesical instillation) in anthracyclines treatment-failed…
- Trial name
- NCT06766266
- Testing
- Irinotecan liposome II combination therapy regimen
- Where
- China
- Volunteers
- 18 people
- Sponsor
- First Affiliated Hospital of Chongqing Medical University
Urothelial Carcinoma, Bladder Cancer
Neoadjuvant Nivolumab With and Without Urelumab in Cisplatin-Ineligible or Chemotherapy-refusing Patients With Muscle-Invasive Urothelial Carcinoma of the Bladder
This study evaluates the post cystectomy CD8+ tumor response of patients receiving Nivolumab plus Urelumab versus Nivolumab alone.
- Trial name
- NCT02845323
- Testing
- Nivolumab in combination with Urelumab, Nivolumab monotherapy
- Where
- 5 sites in United States
- Volunteers
- 15 people
- Sponsor
- Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
Urothelial Carcinoma Bladder, Sperm Count, Low
Effect of Intravesical B.C.G and Gemcitabine on Semen Analysis and Testicular Volume in NMIBC
To evaluate the effects of local intravesical B.C.G and gemcitabine on semen quality and testicular volume.
- Conditions
- Urothelial Carcinoma Bladder, Sperm Count, Low, Testis; Fibrosis, Non Muscle Invasive Bladder Cancer
- Trial name
- NCT05701332
- Testing
- Bacillus Calmette Guerin, Gemcitabine HCL (Gemzar)
- Where
- Egypt
- Volunteers
- 86 people
- Sponsor
- Assiut University